PMID- 33103874
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230320
IS  - 2724-6116 (Electronic)
IS  - 2724-6116 (Linking)
VI  - 48
IP  - 1
DP  - 2023 Mar
TI  - Increased expression of serum IL-18 and IL-18R in newly diagnosed type 2 diabetes 
      mellitus.
PG  - 35-41
LID - 10.23736/S2724-6507.20.03271-X [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disorder 
      in which genetic, sedentary lifestyle, obesity, and environmental factors come 
      together to produce insulin resistance in target tissues, leading to 
      hyperglycemia. Evidence reveals that inflammation may play an essential role in 
      the pathogenesis of T2DM. Interleukin-18 (IL-18), a proinflammatory cytokine, 
      plays a crucial role in the acute and chronic inflammatory process. The 
      association of IL-18 levels with IL-18R expression in T2DM has not been 
      investigated so far. The aim of this study was to compare the peripheral changes 
      in serum IL-18 levels and its receptor (IL18R) expression in newly diagnosed T2DM 
      and healthy controls. METHODS: A total of 35 newly diagnosed type 2 diabetic 
      cases and 35 non-diabetic controls were enrolled after obtaining informed 
      consent. Venous whole blood was taken under aseptic conditions. Biochemical 
      parameters were estimated in an auto-analyzer. Serum IL-18 levels were calculated 
      using ELISA, whereas IL-18R expression was determined via RT-PCR. GAPDH was used 
      as an internal control. RESULTS: When compared to non-diabetic controls, the 
      serum IL-18 levels were significantly higher in T2DM patients (P=0.010) along 
      with a significant upregulation of IL18R (P=0.0018). Serum IL-18 levels in T2DM 
      and non-diabetic controls were 669.5 (445) and 498.3 (404.9) pg/mL respectively, 
      and IL-18R showed a fold change of 10.33. CONCLUSIONS: Both serum IL-18 and its 
      receptor IL-18R is significantly higher in newly diagnosed T2DM patients.
FAU - Abhilasha, Abhilasha
AU  - Abhilasha A
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      India.
FAU - Mitra, Prasenjit
AU  - Mitra P
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      India.
FAU - Suri, Smriti
AU  - Suri S
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      India.
FAU - Saxena, Indu
AU  - Saxena I
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, 
      India.
FAU - Shukla, Ravindra
AU  - Shukla R
AD  - Department of Endocrinology and Metabolism, All India Institute of Medical 
      Sciences, Jodhpur, India.
FAU - Shukla, Kamla Kant
AU  - Shukla KK
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      India.
FAU - Sharma, Praveen
AU  - Sharma P
AD  - Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 
      India - praveensharma55@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Italy
TA  - Minerva Endocrinol (Torino)
JT  - Minerva endocrinology
JID - 101777342
RN  - 0 (Interleukin-18)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/diagnosis/genetics
MH  - Interleukin-18/genetics
MH  - Cytokines
MH  - Inflammation
MH  - *Insulin Resistance
EDAT- 2020/10/27 06:00
MHDA- 2023/03/21 06:00
CRDT- 2020/10/26 11:42
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2020/10/26 11:42 [entrez]
AID - S0391-1977.20.03271-X [pii]
AID - 10.23736/S2724-6507.20.03271-X [doi]
PST - ppublish
SO  - Minerva Endocrinol (Torino). 2023 Mar;48(1):35-41. doi: 
      10.23736/S2724-6507.20.03271-X. Epub 2020 Oct 26.